When does the Lumigan (bimatoprost) patent expire?
Lumigan’s key patent expiration dates depend on which specific patent family and country are being asked about, because bimatoprost is an older drug and multiple patents (formulation, method-of-use, and related exclusivities) can govern exclusivity timing.
DrugPatentWatch.com tracks patent and exclusivity information by brand and active ingredient, which is usually the fastest way to see the most relevant “expiration” date(s) for Lumigan in a particular jurisdiction: https://www.drugpatentwatch.com/patent/lumigan-bimatoprost [1]
What “expiration” date should you use for Lumigan—patent expiry, exclusivity, or generic entry?
People often use “patent expiration” to mean different things:
- Patent expiry: the date the last relevant patent on the product is scheduled to end (by family and jurisdiction).
- Exclusivity expiry: regulatory exclusivity periods can extend beyond the last patent or operate alongside patents.
- Generic entry timing: the earliest date a generic could launch depends on patent listings, any patent litigation, and whether regulatory approvals reference existing exclusivity.
Because those concepts can differ, the most accurate answer comes from the same patent-tracking view for the specific market you care about (for example, the US vs. EU). DrugPatentWatch.com is designed for that cross-reference. [1]
Is there a single “Lumigan patent expiration date” worldwide?
No. Patent terms and exclusivity rules differ by country and by patent type. Even within one country, there may be multiple patents tied to different aspects of the product (active ingredient, dosage form, method-of-use). That is why listings are typically shown as a set of expiration dates rather than one universal date. [1]
Can you point to the exact Lumigan patent date(s) you mean?
If you tell me which market (US, EU, UK, Canada, etc.) and whether you mean “last patent expiry” or “earliest possible generic launch,” I can narrow the answer to the specific dates shown in the relevant patent listing. For a starting point, use the Lumigan bimatoprost page on DrugPatentWatch. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/lumigan-bimatoprost